Meridian Biopharmaceuticals is dedicated to develop innovative cancer immune therapy drugs. Cancer is one of the leading causes of death in the developed countries and the second major killer worldwide. In particular, metastatic disease stages of cancer are not (or not sufficiently) amenable to standard cancer therapy such as surgery, radiotherapy or chemotherapy, and are responsible for the majority of deaths of cancer patients.
Meridian Biopharmaceuticals´ innovative cancer immune therapy drug candidates primarily aim at destruction of disseminated tumor cells and micro-metastases which often remain after standard therapies and to prevent reoccurrence of the tumor and the development of metastases.